Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourth BNT162b2 Dose in Sheba HCW
NCT05231005Phase 4Active, not recruiting
- Sponsor
- Sheba Medical Center
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Sheba Medical Center. Started Dec 2021; status: active, not recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05231005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231005.